Name: 2018 Joint Statistical Meetings
Start: 2018-07-28T07:00:00+00:00
End: 2018-08-02
Location: Vancouver Convention Centre

Keyword Search

Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme

Keyword Search Criteria: estimand returned 13 record(s)

Sunday, 07/29/2018

Causal Estimands and Confidence Intervals Associated with Wilcoxon-Mann-Whitney Tests in Randomized Experiments
Michael Fay, National Institute of Allergy and Infectious Diseases; Erin Gabriel, Karolinska Institute; Joanna H Shih, National Cancer Institute; Dean Follmann, NIAID; Erica H Brittain, National Institute of Allergy and Infectious Diseases
4:35 PM

Monday, 07/30/2018

Symptom Trials Vs Morbidity/Mortality Trials: Are Different Estimands Required?
Steven Snapinn, Amgen, Inc.
8:35 AM

A Decision Tool for Causal Inference and Observational Data Analysis Methods in Comparative Effectiveness Research (DECODE CER)
Douglas Landsittel, University of Pittsburgh; (Joyce) Chung-Chou H. Chang, University of Pittsburgh; Sally C. Morton, Virginia Tech
8:55 AM

Recurrent Event Estimands: With or Without Competing Terminal Event
Jiawei Wei, Novartis
8:55 AM

Assessment of a Treatment Effect for Recurrent Event Data in the Presence of a Terminal Event
Philip Hougaard, Lundbeck
9:15 AM

Tuesday, 07/31/2018

The Importance of Protocol Objectives to the Statistical Analysis
Richard McNally, Covance-Chiltern

Statistical Leadership in Clinical Trials: Opportunities from the Draft Estimand Guidance
Jonathan Siegel, Bayer HealthCare Pharmaceuticals Inc.
9:50 AM

What Do We Know About Estimators for the Treatment Policy Estimand?
Elena Polverejan, Janssen R&D; Vladimir Dragalin, Janssen R&D
2:05 PM

Undiluting the Treatment Effect
Thomas Permutt, Food and Drug Administration
2:55 PM

Wednesday, 08/01/2018

On Causal Inference in the Presence of Limited Overlap
Tingting Zhou, University of Michigan; Michael Elliott, University of Michigan; Roderick J Little, University of Michigan

How the ICH E9 Addendum Influenced a Phase III Clinical Trial with a Radiographic Endpoint
Ruvie Martin, Novartis Pharmaceuticals
11:50 AM

Thursday, 08/02/2018

Practical Considerations in Planning and Implementing Aggregate Safety Monitoring
Bill Wang, Merck
9:35 AM

Using an Estimand Approach in Your Next Clinical Trial
Frank Bretz, Novartis Pharma AG; Steven Gilbert, Pfizer; Douglas S. Lee, Pfizer; Jared Christensen, Pfizer; Macaulay Okwuokenye, Syros Pharmaceuticals Inc
10:35 AM

JSM 2018 Online Program

Keyword Search

American Statistical Association